Literature DB >> 35583827

Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer.

Ying Fan1,2, Rui Sun3,4, Zhizhong Wang3,4, Yuying Zhang2, Xiao Xiao2, Yizhe Liu2, Beibei Xin2, Hui Xiong2, Daru Lu5,6, Jie Ma7,8.   

Abstract

PURPOSE: Mesenchymal-epithelial transition (MET) amplification is one of the mechanisms accounting for the resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung cancer patients, as well as the poor prognosis. Fluorescence in situ hybridization (FISH) is the most widely used method for MET amplification detection. However, it is inapplicable when tissue samples were unavailable. Herein, we assessed the value of droplet digital PCR (ddPCR) in MET copy number gain (CNG) detection in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKIs.
MATERIALS AND METHODS: A total of 103 cancer tissues and the paired peripheral blood samples from NSCLC patients were collected for MET CNG detection using ddPCR. In parallel, MET amplification in tissue samples was verified by FISH. Also, the relationships between MET CNG and EGFR T790M, as well as the EGFR-TKI resistance were also evaluated using Chi-square or Fisher's exact tests. RESULT: The concordance rate of ddPCR and FISH in detecting MET CNG in tissue samples was 100% (102/102), and it was 94.17% (97/103) for ddPCR method in detecting the MET CNG among peripheral blood and tissue samples. No statistical difference was observed between MET amplification and EGFR T790M (p = 0.65), while MET amplification rate was significantly increased in patients with resistance to third generations of EGFR-TKIs as compared with patients with resistance to first/second EGFR-TKIs (p < 0.05).
CONCLUSIONS: ddPCR is an alternative method to detect MET CNG in both tissues and peripheral blood samples, which is of worthy in clinical promotion.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  EGFR T790M; FISH; Liquid biopsy; MET amplification; NSCLC; ddPCR

Year:  2022        PMID: 35583827     DOI: 10.1007/s00432-022-04048-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  56 in total

1.  MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.

Authors:  D Ross Camidge; Kurtis D Davies
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

Review 2.  Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).

Authors:  Re-I Chin; Kevin Chen; Abul Usmani; Chanelle Chua; Peter K Harris; Michael S Binkley; Tej D Azad; Jonathan C Dudley; Aadel A Chaudhuri
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

3.  A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

Authors:  Eric Angevin; Gianluca Spitaleri; Jordi Rodon; Katia Dotti; Nicolas Isambert; Stefania Salvagni; Victor Moreno; Sylvie Assadourian; Corinne Gomez; Marzia Harnois; Antoine Hollebecque; Analia Azaro; Alice Hervieu; Karim Rihawi; Filippo De Marinis
Journal:  Eur J Cancer       Date:  2017-11-14       Impact factor: 9.162

Review 4.  Lung cancer: epidemiology, etiology, and prevention.

Authors:  Charles S Dela Cruz; Lynn T Tanoue; Richard A Matthay
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

Review 5.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors:  Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-10-26       Impact factor: 15.609

Review 6.  Circulating tumor DNA and liquid biopsy in oncology.

Authors:  David W Cescon; Scott V Bratman; Steven M Chan; Lillian L Siu
Journal:  Nat Cancer       Date:  2020-03-20

7.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Authors:  James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi Gazdar; Harvey Pass; Valerie Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Authors:  Jacob J Chabon; Andrew D Simmons; Alexander F Lovejoy; Mohammad S Esfahani; Aaron M Newman; Henry J Haringsma; David M Kurtz; Henning Stehr; Florian Scherer; Chris A Karlovich; Thomas C Harding; Kathleen A Durkin; Gregory A Otterson; W Thomas Purcell; D Ross Camidge; Jonathan W Goldman; Lecia V Sequist; Zofia Piotrowska; Heather A Wakelee; Joel W Neal; Ash A Alizadeh; Maximilian Diehn
Journal:  Nat Commun       Date:  2016-06-10       Impact factor: 14.919

10.  Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.

Authors:  Roberta Castiglione; Christina Alidousty; Barbara Holz; Svenja Wagener; Till Baar; Carina Heydt; Elke Binot; Susann Zupp; Anna Kron; Jürgen Wolf; Sabine Merkelbach-Bruse; Hans Christian Reinhardt; Reinhard Buettner; Anne Maria Schultheis
Journal:  Mod Pathol       Date:  2018-11-20       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.